The Ruling: Supreme Court Overturns Prometheus Patents
By Mari Serebrov
Wednesday, March 21, 2012
WASHINGTON In a decision that will have biotechs reviewing their process patents, the Supreme Court Tuesday ruled that Prometheus Laboratories Inc.'s patents for calibrating the proper dosage of thiopurine drugs used to treat autoimmune diseases are not patentable because they involve laws of nature.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.